Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has shared an announcement.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that it, along with its subsidiary Innogen Technology, subscribed to a structured deposit product from the Bank of Ningbo for RMB 125,000,000. This move is part of the company’s strategy to maximize returns on idle funds through treasury management, leveraging low-risk wealth management products offered by reputable banks in the PRC. The structured deposit is expected to provide a reasonable return compared to current savings or fixed deposit rates, with the principal amount fully refundable, posing minimal risk to the company.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a holding company primarily engaged in the research, development, and commercialization of pharmaceutical products. Its subsidiary, Innogen Technology, focuses on pharmaceutical research, development, and production.
Average Trading Volume: 489,009
Learn more about 2591 stock on TipRanks’ Stock Analysis page.